Sugi Predict

Sugi Predict / Compounds / SCHEMBL4468362

SCHEMBL4468362

SCHEMBL4468362

C[C@@H]1[C@@H](O)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ RECQL P46063 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ PREP P48147 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15731577 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL29222095 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL20514898 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL7852372 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL2198040 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL2390472 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL31153617 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL23765675 0.90 CHRM2 (0.42) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL2913442 0.90 HSD17B10 (0.49) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL2917078 0.90 HSD17B10 (0.49) CHRM2CHRM1CHRM3HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 — — US disclosed
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-01-22 — — US disclosed
EP-4600246-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE Public University Corporation Yokohama City University (JP) 2025-08-13 — — EP disclosed
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
US-12281124-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors HOFFMANN-LA ROCHE INC. (US) 2025-04-22 — — US disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 — — CN disclosed
EP-4474017-A2 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-11 — — EP disclosed
EP-3837263-B1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN LA ROCHE (CH) 2024-07-03 — — EP disclosed
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-05-09 — — US disclosed
WO-2024075696-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE 公立大学法人横浜市立大学 2024-04-11 — — WO disclosed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 — — US disclosed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 — — US disclosed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 — — US disclosed
WO-2009137130-A2 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2009-11-12 — — WO disclosed
US-7368453-B2 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
US-7368453-B2 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
US-7368453-B2 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
EP-1651229-A1 GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS Chiron Corporation (US) 2006-05-03 — — EP disclosed
US-20050192297-A1 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION GLAXOSMITHKLINE 2005-09-01 — — US disclosed
WO-2004112793-A1 GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS CHIRON CORPORATION (US) 2004-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LIPA, LPL CHRM2 661/4885CHRM1 404/4885CHRM3 412/4885
US-12281124-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors LIPC, LPL, MGLL CHRM2 1057/4885CHRM1 679/4885CHRM3 1370/4885
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE SMG1, RACK1, TIA1 CHRM2 2221/4885CHRM1 804/4885CHRM3 2235/4885
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL CHRM2 1057/4885CHRM1 679/4885CHRM3 1370/4885
US-20050192297-A1 Quinazolinone compounds with reduced bioaccumulation MC4R, MC2R, MC3R CHRM2 79/4885CHRM1 51/4885CHRM3 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.